211 related articles for article (PubMed ID: 29693178)
1. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
Zhan SJ; Liu B; Linghu H
Oncol Rep; 2018 Jun; 39(6):2653-2663. PubMed ID: 29693178
[TBL] [Abstract][Full Text] [Related]
2. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
3. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
Wu M; Sun Y; Wu J; Liu G
Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
[TBL] [Abstract][Full Text] [Related]
4. Exploration of the sequential gene changes in epithelial ovarian cancer induced by carboplatin via microarray analysis.
Wei S; Liu J; Shi Y; Zhang X; Yang Y; Song Q
Mol Med Rep; 2017 Sep; 16(3):3155-3160. PubMed ID: 28713952
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
6. Identification of Differentially Expressed Genes (DEGs) Relevant to Prognosis of Ovarian Cancer by Use of Integrated Bioinformatics Analysis and Validation by Immunohistochemistry Assay.
Zhang L; Sun L; Zhang B; Chen L
Med Sci Monit; 2019 Dec; 25():9902-9912. PubMed ID: 31871312
[TBL] [Abstract][Full Text] [Related]
7. EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM.
Naskou J; Beiter Y; van Rensburg R; Honisch E; Rudelius M; Schlensog M; Gottstein J; Walter L; Braicu EI; Sehouli J; Darb-Esfahani S; Staebler A; Hartkopf AD; Brucker S; Wallwiener D; Beyer I; Niederacher D; Fehm T; Templin MF; Neubauer H
Mol Cancer Res; 2020 Feb; 18(2):278-286. PubMed ID: 31704732
[TBL] [Abstract][Full Text] [Related]
8. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance.
Zhang M; Luo SC
Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909918
[TBL] [Abstract][Full Text] [Related]
10. Identification of key molecular markers in epithelial ovarian cancer by integrated bioinformatics analysis.
Qin W; Yuan Q; Liu Y; Zeng Y; Ke D; Dai X; Shuai Y; Hu J; Shi H
Taiwan J Obstet Gynecol; 2021 Nov; 60(6):983-994. PubMed ID: 34794761
[TBL] [Abstract][Full Text] [Related]
11. Prediction of chemo-response in serous ovarian cancer.
Gonzalez Bosquet J; Newtson AM; Chung RK; Thiel KW; Ginader T; Goodheart MJ; Leslie KK; Smith BJ
Mol Cancer; 2016 Oct; 15(1):66. PubMed ID: 27756408
[TBL] [Abstract][Full Text] [Related]
12. Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers.
Sun Q; Zhao H; Zhang C; Hu T; Wu J; Lin X; Luo D; Wang C; Meng L; Xi L; Li K; Hu J; Ma D; Zhu T
Oncotarget; 2017 Jun; 8(26):42983-42996. PubMed ID: 28562334
[TBL] [Abstract][Full Text] [Related]
13. Screening and identification of key biomarkers in hepatocellular carcinoma: Evidence from bioinformatic analysis.
Li L; Lei Q; Zhang S; Kong L; Qin B
Oncol Rep; 2017 Nov; 38(5):2607-2618. PubMed ID: 28901457
[TBL] [Abstract][Full Text] [Related]
14. High-efficient Screening Method for Identification of Key Genes in Breast Cancer Through Microarray and Bioinformatics.
Liu Z; Liang G; Tan L; Su AN; Jiang W; Gong C
Anticancer Res; 2017 Aug; 37(8):4329-4335. PubMed ID: 28739725
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of core serous epithelial ovarian cancer genes as potential prognostic markers and indicators of the underlying molecular mechanisms using an integrated bioinformatics analysis.
Zhang YB; Jiang Y; Wang J; Ma J; Han S
Oncol Lett; 2019 Nov; 18(5):5508-5522. PubMed ID: 31612059
[TBL] [Abstract][Full Text] [Related]
16. Data Mining of Differentially Expressed Genes in Ovarian Epithelial Carcinoma: Implications in Precise Medicine.
Zhao J; Gao H; He Y
Curr Top Med Chem; 2021 Oct; 21(14):1285-1300. PubMed ID: 34238161
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of NEK11 is associated with drug resistance in ovarian cancer.
Liu X; Gao Y; Lu Y; Zhang J; Li L; Yin F
Int J Oncol; 2014 Sep; 45(3):1266-74. PubMed ID: 24969318
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
[TBL] [Abstract][Full Text] [Related]
19. Identification of Key Genes and Pathway for Ovarian Neoplasms Using the OVDM1 Cell Line Based on Bioinformatics Analysis.
Yin S; Du J; Zhang J; Zhang X; Ma K
Med Sci Monit; 2019 Jun; 25():4305-4313. PubMed ID: 31177266
[TBL] [Abstract][Full Text] [Related]
20. Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.
Yan JQ; Liu M; Ma YL; Le KD; Dong B; Li GH
Exp Biol Med (Maywood); 2022 Jun; 247(11):910-920. PubMed ID: 35285286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
